Compare Cassava Sciences Inc (FLNA) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs iShares MSCI China ETF — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while iShares MSCI China ETF trades at $54.1. The key difference: iShares MSCI China ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | MCHI | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $4.64 | $66.99 |
52-Week Low | $1.09 | $50.48 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
MCHI trades at $54.10, up 1.63% with a bullish technical signal from moving averages. The stock shows strong momentum with ADX indicating a strong trend, though RSI levels suggest potential overbought conditions. Recent news highlights China's AI and manufacturing resurgence, with exports growing 19.4% year-over-year in May 2026 (Reuters, 2026-06-08).
The outlook remains cautiously optimistic given China's $295 billion AI investment plan (Bloomberg, 2026-06-09) and factory rebound. However, risks include US-China trade tensions and concerns about Chinese equities being value traps. Analyst sentiment is mixed with some maintaining sell ratings due to structural headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
